Evidence map›Paper›PMID 40808925›Full record

ArticleFrontiers in neurology2025

Early cerebrospinal fluid elevations of pTau-217 in severe traumatic brain injury subjects.

Hamad Yadikar, Firas H Kobeissy, Claudia Robertson, Spyridoula Tsetsou, John B Williamson, Damon G Lamb, Amy K Wagner, Todd Kibaugh, Shih-Han Kao, Zhifeng Kou and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hamad YadikarDepartment of Biological Sciences, Faculty of Science, Kuwait University, Kuwait City, Kuwait.
Firas H KobeissyCenter for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, Atlanta, GA, United States.
Claudia RobertsonDepartment of Neurosurgery, Baylor College of Medicine, Houston, TX, United States.
Spyridoula TsetsouDepartment of Neurosurgery, Baylor College of Medicine, Houston, TX, United States.
John B WilliamsonBrain Rehabilitation Research Center, Malcom Randall VA Medical Center, Gainesville, FL, United States.
Damon G LambBrain Rehabilitation Research Center, Malcom Randall VA Medical Center, Gainesville, FL, United States.
Amy K WagnerDepartment of Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA, United States.
Todd KibaughResuscitation Science Center of Emphasis, Department of Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia, School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
Shih-Han KaoResuscitation Science Center of Emphasis, Department of Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia, School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
Zhifeng KouCollege of Engineering, School of Medicine, Wayne State University, Detroit, MI, United States.
Robert D WelchDepartment of Emergency Medicine, Wayne State University School of Medicine, Detroit, MI, United States.
Jose-Miguel YamalDepartment of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, United States.
Luis Leon-NoveloDepartment of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, United States.
Richard RubensteinDepartment of Neurology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States.
Kevin K W WangCenter for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, Atlanta, GA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Tauopathies, including Alzheimer's disease (AD), feature abnormal accumulations of hyperphosphorylated Tau protein; however, their biomarker potential in traumatic brain injury (TBI) is not well-defined. This study investigated whether cerebrospinal fluid (CSF) phosphorylated Tau at threonine-217 (pTau-217) could serve as an early biomarker for severe TBI (sTBI). Methods: CSF samples from 26 sTBI patients, collected between 6 and 240 h post-injury, and 19 healthy controls were analyzed using an optimized direct enzyme-linked immunosorbent assay (ELISA; sensitivity <4.7 pg/mL) for pTau-217 detection, complemented by Western blot validation. Temporal analysis, ROC curves, and trajectory clustering were used for interpretation. Results: CSF pTau-217 levels were significantly elevated in sTBI patients at 6, 12, 18, 24, and 48 h post-injury compared to controls ( Discussion: These findings indicate that CSF pTau-217 is a sensitive and early biomarker of acute tau pathology in sTBI. Its diagnostic performance and association with axonal injury and outcome support its utility, though longitudinal validation in larger cohorts is required to confirm clinical relevance.

Indexed as

CSF biomarkersdiagnostic biomarkersneurotrauma prognosticspTau-217traumatic brain injury

Identifiers

PMID40808925
PMCPMC12344560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.